Systemic Lupus Erythematosus (SLE) Update Bulletin 2022: Gain Insights on the Latest Events Happening in the Treatment Landscape - ResearchAndMarkets.com

2022-11-08
Business Wire
DUBLIN--(BUSINESS WIRE)--The "Systemic Lupus Erythematosus (SLE): Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.
Gain new key opinion leader (KOL) insights on the latest events happening in Systemic Lupus Erythematosus (SLE) treatment landscape.
Topics covered include expert opinions on the prospects of the Phase III BLISS-BELIEVE study which will assess co-administration of SC Benylsta (GSK's belimumab) and a single cycle of IV Rituxan/MabThera (rituximab; Roche/Biogen).
The KOLs also imparted their views on the results of a Phase II study investigating Stelara (ustekinumab; Janssen Biotech) for the treatment of SLE, and the potential for XTL Biopharmaceuticals' edratide as well as Corbus Pharmaceuticals's anabasum.
Business Questions:
How do KOLs view the combination of belimumab and rituximab for the treatment of SLE? Do KOLs harbour any concerns about combining these two biologic agents?
How do experts view the results of ustekinumab's Phase II study?
What advantages does ustekinumab have over other pipeline SLESLE agents?
How do KOLs perceive edratide's mechanism of action and preliminary trial results?
How optimistic are KOLs about edratide's prospects as a treatment for SLE?
Do KOLs perceive anabasum's mechanism of action to be promising?
How do KOLs view this agent's safety profile?
For more information about this newsletter visit https://www.researchandmarkets.com/r/rggx5q
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。